PFE · Pfizer Inc
$27.41
-0.40 (-1.42%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$163.41B
Shares
5.70B
Volume · Oct 5
17.65M
Avg daily vol (3M)
36.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.80
Open$28.15
Day$27.44–28.16
52W close$23.67–29.02
Avg vol 30d33.0M
Short int155.2M · 2.7% float · 4.9d
Short vol49%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 4 wks
filed Aug 4, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$63.70B
Trailing 12 months
Net income (TTM)
$4.33B
Trailing 12 months
Revenue growth YoY
+2.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
36.6
Trailing earnings · reciprocal yield 2.7%
FCF yield
6.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.1%
Year over year · fewer shares
Price change (1Y)
+2.7%
Trailing year
Short interest
2.7%
Latest settlement · 4.9 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Pfizer raised the midpoint of its full-year 2026 revenue guidance by $500M (to $60.5–$62.5B) while reaffirming adjusted diluted EPS guidance of $2.80–$3.00, announced $2.5B of additional productivity savings through 2029, and posted 18% operational growth in launched and acquired products, though Q2 GAAP results swung to a $(0.04) reported loss on a $4.3B intangible-impairment charge tied to the failed SigVie-002 lung cancer readout and Oxbryta.
Bullish
- + Raised full-year 2026 revenue guidance by $500M at midpoint to $60.5–$62.5B while reaffirming $2.80–$3.00 adjusted diluted EPS
- + Announced an additional $2.5B in productivity/net-cost savings through 2029, lifting cost-base program savings to $6.7B and manufacturing program savings to ~$3B
- + Q2 adjusted diluted EPS of $0.77 exceeded the company's expectation and marked 10 consecutive beats on EPS and 9 of the last 10 quarters on revenue
- + Padcev plus pembrolizumab received FDA approval for muscle-invasive bladder cancer regardless of cisplatin eligibility and grew 23% operationally in Q2
Bearish
- − Q2 GAAP reported loss per share of $(0.04) after a $4.3B non-cash intangible-asset impairment charge
- − SigVie-002 Phase 3 of sigvotatug vedotin in 2L+ non-squamous NSCLC missed the primary overall survival endpoint, driving a $3.8B IPR&D impairment
- − Oxbryta $525M impairment after FDA discussions found no viable pathway to return the product to the U.S. market
- − Paxlovid revenue was down 95% operationally and Comirnaty down 34% operationally in Q2 on low infection levels and narrower U.S. vaccine recommendation
- − Q2 GAAP Cost of Sales rose to 27.2% of revenues from 25.8% on unfavorable mix and higher amortization of fair-value step-up from the Oxbryta impairment
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very Low
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
+2%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
77%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+2%
trailing
YTD return
+12%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow
Distributing
16 of 2,853 funds reported for Sep 30 · net -353 sh shares · +1 new
Insider flow
Accumulating
Net +$2.9M over 90 days · 25% sells
Short interest
Rising
2.72% of float · ▲ +2.4% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2,853 holders — near 3-yr low, contrarian setup
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−2%
Y/Y
EPS growth
−4%
Y/Y
Free cash flow
$9.1B
Valuation
P/E 37.7
in line
Buyback
$3.3B
remaining
Balance sheet
$63.5B
net debt
Quant / Vol
risk profile
Volatility
22%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
1.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Revenues
· full-year 2026
Initiated
$60.5B – $62.5B
prior FY $62.58B
midpoint −1.7% Y/Y
Effective Tax Rate on Adjusted Income
· full-year 2026
Non-GAAP
Maintained
15%
May 5, 2026
15%
changed to
Aug 4, 2026
15%
Guided vs delivered
· last 3 settled
Revenues
Full-Year 2024
guided $58.5B – $61.5B
$63.63B
Beat +6.0%
Revenues
Full-Year 2023
guided $58B – $61B
$59.55B
In line
Total company revenue
2021
guided $81B – $82B
$81.29B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
77%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow
Distributing
16 of 2,853 funds reported for Sep 30 · net -353 sh shares · +1 new
Insider flow
Accumulating
Net +$2.9M over 90 days · 25% sells
Short interest
Rising
2.72% of float · ▲ +2.4% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2,853 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $24
Now $28 · 77%
Range high $29
vs 200-day avg +5%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PFE
this stock
Pfizer Inc
|
$163.41B | +11.6% | -1.6% | 37.7 | 2.7% |
|
LLY
ELI LILLY & Co
|
$1.11T | +6.3% | +44.7% | 39.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$653.61B | +23.7% | +6.0% | 31.5 | 0.9% |
|
ABBV
AbbVie Inc.
|
$466.80B | +15.0% | +8.6% | 74.6 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$367.07B | +37.1% | +1.3% | 119.0 | 1.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PFE | -3.0% | -3.5% | +1.7% | -2.5% | +11.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -2.8% | -3.1% | -10.5% | -3.4% | -1.2% |
Capital returns
Buyback program
· as of Aug 4, 2026
Authorized
$6.80B
Spent (derived)
$3.50B
Remaining
$3.30B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.